Rashmi Chugh, MD
Maisel Research Professor of Translational/Clinical Oncology
Clinical Professor of Internal Medicine and Service Chief
Internal Medicine
Medical School
Michigan Medicine
Internal Medicine - Hematology/Oncology
1500 East Medical Center Drive, C407 MIB
Ann Arbor, Michigan 48109
Internal Medicine - Hematology/Oncology
1500 East Medical Center Drive, C407 MIB
Ann Arbor, Michigan 48109
Available to mentor
Rashmi Chugh, MD
Clinical Professor
Manage Your Profile
Center Memberships
-
Center MemberRogel Cancer Center
Recent Publications
-
Seiden E, Sauer S, Hiscock E, Le NN, Hellens A, Inda M, Fuller A, Veluvolu SM, Hinshaw R, Tolstyka ZP, Levine E, Chugh R, Laetsch TW, Neamati N, Wilson-Robles H, Khanna C, Warshawsky D, Grohar PJ. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 1151 - 1151.Journal ArticleAbstract 1151: Targeting high risk osteosarcoma: MYC modulation alters metastasis
DOI:10.1158/1538-7445.am2026-1151 -
Gounder M, Schöffski P, Jones RL, Stacchiotti S, Demetri GD, Cote GM, Agulnik M, Chugh R, Jahan T, Gupta AA, Chen TW-W, Ratan R, Dileo P, Drilon A, Malouf GG, Szanto A, Gupta N, Tannir NM. Nat Commun, 2026 Mar 25;Journal ArticleTazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.
DOI:10.1038/s41467-026-69708-2 PMID: 41882006 -
Chugh R, Wilky B, Alese O, Monga V, Sankhala KK, Heinrich M, Ratan R, Berlanga P, De Haan JJ, Garcia AS, Provenzano S, Davis EJ, Brahmi M, O'Neill B, Piccione E, Kalabus J, Willis K, Li Y, Garcia J, Chawla SP. ESMO Rare Cancers, 2026 Mar 11; 5: 100290Journal Article84MO Phase I study of the tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) combined with irinotecan (I) and temozolomide (T) in adolescents and adults with Ewing sarcoma
DOI:10.1016/j.esmorc.2026.100290 -
Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Polson KM, Yalamanchili S, DeBoer C, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Dickson MA. Future Oncol, 2026 Jan; 22 (1): 1 - 13.Journal ArticleA plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.
DOI:10.1080/14796694.2025.2574811 PMID: PMC12773610 -
Wytiaz V, Marks A, Mayers A, Shami S, Schuetze S, Chugh R. Palliative Care and Social Practice, 2026 Jan 1; 20:Journal ArticleAn analysis of palliative care in adolescents and young adults with soft tissue and bone sarcomas
DOI:10.1177/26323524261415905 -
Wytiaz V, Chugh R. Expert Opinion on Pharmacotherapy, 2026 Jan 1;Journal ArticleInvestigating vimseltinib in tenosynovial giant cell tumors
DOI:10.1080/14656566.2026.2622472 PMID: 41582091 -
Perry KD, Mehra R, Leathersich A, Abdulfatah E, Rottmann D, Schechter S, McHugh J, Narayan SP, Angeles CV, Chugh R, Conway K, Brown N. International Journal of Surgical Pathology, 2026 Jan 1;Journal ArticleRetroperitoneal Schwannoma with a Novel PRCC::TFE3 Fusion: Expanding the Spectrum of Schwannomas with a TFE3 Gene Rearrangement
DOI:10.1177/10668969261442124 -
Grohar PJ, Heise R, Wedekind MF, Ballman K, Mascarenhas L, DuBois SG, Maki RG, Boguslawski EA, Gedminas JM, Wilson ER, Thomas E, Segers B, Surrey LF, Ricker C, Klega K, Navid F, Lam GY, The S, Kaufman R, Roberts RD, Hayashi M, Mena E, Overman L, Peer C, Schmidt K, Diamond MS, Figg WD, Bagatell R, Liza Lindenberg M, Choyke PL, Crompton BD, Widemann BC, Glod JW, Laetsch TW, Reinke DK, Chugh R. Nature Medicine, 2026 Jan 1;Journal ArticleTrabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial
DOI:10.1038/s41591-026-04340-7
